vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more
vTv Therapeutics Inc (VTVT) - Net Assets
Latest net assets as of September 2025: $70.54 Million USD
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has net assets worth $70.54 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($99.49 Million) and total liabilities ($28.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.54 Million |
| % of Total Assets | 70.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | 277.04% |
| 10-Year Change | N/A |
| Growth Volatility | 293.53 |
vTv Therapeutics Inc - Net Assets Trend (2013–2024)
This chart illustrates how vTv Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for vTv Therapeutics Inc (2013–2024)
The table below shows the annual net assets of vTv Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.30 Million | +177.10% |
| 2023-12-31 | $-18.55 Million | -417.67% |
| 2022-12-31 | $5.84 Million | -61.64% |
| 2021-12-31 | $15.22 Million | +301.32% |
| 2020-12-31 | $3.79 Million | +142.91% |
| 2019-12-31 | $-8.84 Million | +89.33% |
| 2018-12-31 | $-82.85 Million | +45.15% |
| 2017-12-31 | $-151.05 Million | -66.09% |
| 2016-12-31 | $-90.94 Million | -16.64% |
| 2015-12-31 | $-77.97 Million | +84.37% |
| 2014-12-31 | $-498.81 Million | -64.23% |
| 2013-12-31 | $-303.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to vTv Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 401500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.00K | 0.26% |
| Other Components | $311.88 Million | 2556.64% |
| Total Equity | $12.20 Million | 100.00% |
vTv Therapeutics Inc Competitors by Market Cap
The table below lists competitors of vTv Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polight ASA
OL:PLT
|
$106.53 Million |
|
B Communications Ltd
PINK:BCOMF
|
$106.54 Million |
|
Sapura Energy Bhd
KLSE:5218
|
$106.55 Million |
|
Tanvex BioPharma Inc
TW:6541
|
$106.58 Million |
|
GalaxiaMoneytree Co.Ltd
KQ:094480
|
$106.44 Million |
|
Niko Semiconductor Co Ltd
TWO:3317
|
$106.43 Million |
|
Nova Klúbburinn hf.
IC:NOVA
|
$106.42 Million |
|
India Motor Parts and Accessories Limited
NSE:IMPAL
|
$106.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in vTv Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -24,680,000 to 12,199,000, a change of 36,879,000.
- Net loss of 18,462,000 reduced equity.
- New share issuances of 52,798,000 increased equity.
- Other factors increased equity by 2,543,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.46 Million | -151.34% |
| Share Issuances | $52.80 Million | +432.81% |
| Other Changes | $2.54 Million | +20.85% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares vTv Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-1478.08 | $36.70 | x |
| 2014-12-31 | $-2402.34 | $36.70 | x |
| 2015-12-31 | $-9.42 | $36.70 | x |
| 2016-12-31 | $-9.53 | $36.70 | x |
| 2017-12-31 | $-623.31 | $36.70 | x |
| 2018-12-31 | $-266.21 | $36.70 | x |
| 2019-12-31 | $-64.73 | $36.70 | x |
| 2020-12-31 | $-67.97 | $36.70 | x |
| 2021-12-31 | $-6.22 | $36.70 | x |
| 2022-12-31 | $-5.59 | $36.70 | x |
| 2023-12-31 | $-11.84 | $36.70 | x |
| 2024-12-31 | $2.11 | $36.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently vTv Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1815.34%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 3.14x
- Recent ROE (-151.34%) is below the historical average (-12.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -4938.83% | 0.06x | 0.00x | $-17.83 Million |
| 2014 | 0.00% | -2330.60% | 0.12x | 0.00x | $13.78 Million |
| 2015 | 0.00% | -5298.27% | 0.01x | 0.00x | $-19.70 Million |
| 2016 | 0.00% | -2579.18% | 0.01x | 0.00x | $-7.26 Million |
| 2017 | 0.00% | -5547.77% | 0.01x | 0.00x | $-1.04 Million |
| 2018 | 0.00% | -63.62% | 1.45x | 0.00x | $374.30K |
| 2019 | 0.00% | -793.70% | 0.30x | 0.00x | $-17.04 Million |
| 2020 | 0.00% | -132.51% | 0.43x | 0.00x | $-488.80K |
| 2021 | 0.00% | -324.27% | 0.16x | 0.00x | $-12.01 Million |
| 2022 | 0.00% | -949.65% | 0.06x | 0.00x | $-18.09 Million |
| 2023 | 0.00% | -225000.00% | 0.00x | 0.00x | $-17.78 Million |
| 2024 | -151.34% | -1815.34% | 0.03x | 3.14x | $-19.68 Million |
Industry Comparison
This section compares vTv Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| vTv Therapeutics Inc (VTVT) | $70.54 Million | 0.00% | 0.41x | $106.52 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |